# Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI‐2620 PET

**Authors:** Johannes Gnörich, Julia Kusche‐Palenga, Carla Palleis, Antonia Neubauer, Lukas Frontzkowski, Alexander Jäck, Agnes Kling, Theresa Bauer, Hannah Eyob, Katharina Probst, Sebastian N. Roemer‐Cassiano, Alexander M. Bernhardt, Sabrina Katzdobler, Lena Marth, Mirlind Zaganjori, Franziska Hopfner, Andreas Zwergal, Jan Häckert, Michael Rullmann, Osama Sabri, Henryk Barthel, Sophia Stöcklein, Rudolf A. Werner, Mikael Simons, Johannes Levin, Jochen Herms, Nicolai Franzmeier, Günter U. Höglinger, Matthias Brendel

PMC · DOI: 10.1002/alz.71195 · Alzheimer's & Dementia · 2026-02-24

## TL;DR

This study shows that [18F]PI-2620 PET can track tau accumulation in progressive supranuclear palsy over time, revealing patterns of progression and saturation.

## Contribution

The study introduces longitudinal [18F]PI-2620 PET as a tool to monitor tau aggregation in PSP and identifies network-based propagation patterns.

## Key findings

- Subcortical tau PET signals increased most in the globus pallidus internus over 21 months.
- Tau accumulation followed functional connectivity patterns across brain regions.
- Post mortem data showed elevated tau PET correlated with higher AT8 pathology despite neuronal loss.

## Abstract

Progressive supranuclear palsy (PSP), a 4‐repeat tauopathy, can be visualized using [18F]PI‐2620 tau positron emission tomography (PET). However, the value of sequential [18F]PI‐2620 imaging for tracking tau accumulation during the disease course has not yet been investigated.

Twenty‐three PSP patients underwent two [18F]PI‐2620 PET scans (interval: 21.4 ± 4.3 months) and were compared to cross‐sectional data from 25 healthy controls. Regional volume of distribution ratio values were analyzed for longitudinal tau changes, clinical correlations, and network‐based propagation. Post mortem analyses examined neuronal density and AT8 tau pathology.

Subcortical tau PET signals increased, strongest in the globus pallidus internus (P < 0.0001). Patients with low baseline tau showed the largest increases. Despite clinical worsening (Progressive Supranuclear Palsy Rating Scale +48%), tau PET change did not correlate with symptom progression. Tau accumulation followed functional connectivity (R = 0.34, P < 0.0001). Post mortem data linked elevated tau PET to higher AT8 burden despite neuronal loss.

[18F]PI‐2620 PET enables monitoring of tau progression in PSP, indicating network‐based tau propagation with saturation in advanced stages.

Longitudinal tau positron emission tomography (PET) reveals subcortical tau progression in progressive supranuclear palsy over 21 months.Tau accumulation shows a non‐linear trajectory with ceiling effects .PET signal remains elevated despite neuronal loss due to residual tau pathology.Functional connectivity predicts similarity in tau accumulation rates across regions.

Longitudinal tau positron emission tomography (PET) reveals subcortical tau progression in progressive supranuclear palsy over 21 months.

Tau accumulation shows a non‐linear trajectory with ceiling effects .

PET signal remains elevated despite neuronal loss due to residual tau pathology.

Functional connectivity predicts similarity in tau accumulation rates across regions.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau)
- **Chemicals:** [18F]PI-2620 (PubChem CID 145722629)
- **Diseases:** progressive supranuclear palsy (MONDO:0019037), PSP (MONDO:0010997)

## Full-text entities

- **Genes:** GPI (glucose-6-phosphate isomerase) [NCBI Gene 2821] {aka AMF, CNSHA4, GNPI, NLK, PGI, PHI}, MSMB (microseminoprotein beta) [NCBI Gene 4477] {aka HPC13, IGBF, MSP, MSPB, PN44, PRPS}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** progressive gait freezing (MESH:D018450), Parkinsonism (MESH:D010302), amyloid (MESH:C000718787), dementia (MESH:D003704), MDS (MESH:C000719191), Neuronal loss (MESH:D009410), Movement Disorder (MESH:D009069), VTr (MESH:D020243), cognitive decline (MESH:D003072), PSP (MESH:D013494), postural instability (MESH:D054972), 4R tauopathies (MESH:D024801), tau aggregation (MESH:C536599), apraxia (MESH:D001072), NFTs (MESH:D055956), neuronal dysfunction (MESH:D009461), vertical gaze palsy (MESH:C565077), Parkinson Disease (MESH:D010300), parkinsonian syndromes (MESH:D020734), neurodegeneration (MESH:D019636), atrophy (MESH:D001284), CBD (MESH:D000088282), AD (MESH:D000544), decline in (MESH:D060825), cortical sensory deficits (MESH:D012678)
- **Chemicals:** Phenylbutyrate (MESH:D010654), [18F]AV-1451 (MESH:C000591008), [18F]florbetaben (MESH:C527756), mCT (MESH:C000709826), neuromelanin (MESH:C014121), formalin (MESH:D005557), glucose (MESH:D005947), eosin (MESH:D004801), [18F]flutemetamol (MESH:C581552), Hematoxylin (MESH:D006416), 4R (-), H&amp;E (MESH:D006371), paraffin (MESH:D010232), 18F]PI-2620 (MESH:C000710692)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932912/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932912/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932912/full.md

---
Source: https://tomesphere.com/paper/PMC12932912